Coronary Compliance Modification by Intravascular Lithotripsy: New Predictor of Stent Expansion in Calcified Coronary Lesions
In heavily calcified coronary lesions treated with IVL, ΔCACom is an independent predictor of SE.
Authors
- Bimmer E.P.M. Claessen (ORCID: https://orcid.org/0000-0002-1703-7921)
- Martijn J. H. van Oort (ORCID: https://orcid.org/0000-0002-0860-6969)
- Hany Girgis (ORCID: https://orcid.org/0000-0002-5985-7880)
- Joëlle Kefer (ORCID: https://orcid.org/0000-0001-8338-908X)
- Aukelien C. Dimitriu‐Leen (ORCID: https://orcid.org/0000-0001-9131-9903)
- José M. Montero Cabezas (ORCID: https://orcid.org/0000-0002-3851-5195)
- Tessel Vossenberg (ORCID: https://orcid.org/0000-0003-1122-2429)
- Brian O. Bingen (ORCID: https://orcid.org/0000-0002-4986-8623)
- Frank van der Kley (ORCID: https://orcid.org/0000-0003-4521-8698)
- Federico Oliveri (ORCID: https://orcid.org/0000-0001-5946-0827)
- J Wouter Jukema
- Ibtihal Al Amri (ORCID: https://orcid.org/0000-0002-2772-7029)
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- Radboud University Nijmegen (NL)
- Leiden University Medical Center (NL)
- Medisch Centrum Leeuwarden (NL)
- Radboud University Medical Center (NL)
- Netherlands Heart Institute (NL)
- Amsterdam University Medical Centers (NL)
- Jeroen Bosch Ziekenhuis (NL)
Publication Details
- Journal
- Journal of the Society for Cardiovascular Angiography & Interventions
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.jscai.2025.102635
- Citations
- 3
- Primary Topic
- Coronary Interventions and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Edwards Lifesciences
- Boston Scientific Corporation
- Amarin Corporation
- InfraRedx
- Abiomed
- Universiteit Leiden
- Novo Nordisk
- Leids Universitair Medisch Centrum
- Abbott Vascular
- Netherlands Heart Institute
- Daiichi Sankyo Europe